Cosyntropin Depot FDA Approval Status
Cosyntropin Depot is an alcohol-free, long-acting formulation of a synthetic ACTH analogue in development for use as a diagnostic in the screening of patients presumed to have adrenocortical insufficiency.
Development timeline for Cosyntropin Depot
|Oct 21, 2019||Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin|
|Dec 20, 2018||Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.